Physician profile
Natalya Shtutman
NPI 1659321610
$6,995.90
in general payments reported to CMS, 2019-2025
32 companies · $968 in 2025
The $968 reported for 2025 was more than what 87% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,539 · 2020: $1,253 · 2021: $877 · 2022: $843 · 2023: $531 · 2024: $985 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,483.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electronic Waveform Lab, INC. | $2,118.21 | 2019-2025 | |
| Abbott Laboratories | $803.71 | 2019-2023 | Proclaim, Eterna |
| Boston Scientific Corporation | $698.46 | 2019-2025 | Intracept, General - Pain Management, Intracept Rf Probe |
| Medtronic, INC. | $654.42 | 2021-2025 | Intellis Adaptivestim, Venaseal, Inceptiv |
| Zyla Life Sciences, INC. | $428.75 | 2019-2020 | |
| Almatica Pharma LLC | $358.54 | 2021-2023 | Gralise, Loreev Xr |
| Scilex Pharmaceuticals INC. | $316.67 | 2019-2025 | |
| Si-Bone, INC. | $215.66 | 2019-2023 | |
| Collegium Pharmaceutical, INC. | $196.94 | 2020-2025 | Belbuca |
| Pfizer INC. | $184.08 | 2019-2024 | |
| Vertos Medical, INC. | $137.74 | 2024 | Mild Device Kit |
| Medtronic USA, INC. | $128.26 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.61 | 2021-2025 | Relistor |
| Saluda Medical Americas, INC. | $88.65 | 2024 | Evoke |
| Horizon Therapeutics Plc | $54.74 | 2020-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $54.62 | 2025 | Senza |
| Biohaven Pharmaceutical Holding Company LTD. | $52.81 | 2022 | |
| Lilly USA, LLC | $47.48 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $47.21 | 2019-2022 | |
| Spr Therapeutics, INC | $36.08 | 2024-2025 | Sprint Pns System |
| Assertio Therapeutics, INC. | $28.61 | 2019-2020 | |
| Nalu Medical, INC. | $27.73 | 2025 | Nalu Neurostimulation System |
| Nevro Corp. | $26.99 | 2019-2022 | |
| Biodelivery Sciences International, INC. | $25.44 | 2019-2020 | |
| Amgen INC. | $21.49 | 2025 | Krystexxa |
| Azurity Pharmaceuticals, INC. | $19.82 | 2024 | Horizant |
| International Rehabilitative Sciences, INC | $19.61 | 2024 | Rs 4i Plus Sequential Stimulator |
| Vertex Pharmaceuticals Incorporated | $16.83 | 2025 | |
| Hikma Pharmaceuticals USA | $16.75 | 2021 | |
| Averitas Pharma INC. | $15.00 | 2023 | Qutenza |
| Abbvie INC. | $14.59 | 2019 | |
| Kaleo, INC. | $12.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalya Shtutman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.